APA to phase out pharma-sponsored CME, dinners

Share this article:

The American Psychiatric Association (APA) will put an end to industry-sponsored continuing medical education (CME) and meals served during its annual meetings, the association said Wednesday.

“It's important to differentiate CME from advertising…and promotional medical education,” said Nada Stotland, president of the APA. “There is data to indicate that goodies from pharmaceutical companies influence physicians. We consider [sponsored] presentations and fancy dinners to be goodies.”

The APA hosts the nation's largest meeting for psychiatrists each May, said Stotland, and industry sponsorships for that meeting vary, but usually account for over $1 million.

The plan will considerably reduce industry-sponsored CME and meals in 2009, said Stotland. The APA will eliminate all such sponsorships over the next two or three years, and possibly sooner, she said.

Accredited CME provides physicians with the credits needed to maintain a valid license according to state law requirements. Concerns over the potential influence or bias inherent in corporate-sponsored CME have prompted some medical schools, including Stanford University, the universities of Massachusetts, Pittsburgh, Kansas and others, to ban direct CME sponsorship entirely.

However, a Manhattan Research survey in February found that only 9% of surveyed physicians were opposed to pharma or device manufacturer-funded CME. Just 8% felt that sponsored CME programs they had attended were biased, according to the survey results. 

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...